BB Biotech Update December 2021

The broader stock market had a very positive 2021. With the roll-out of Pfizer/Biontech and Moderna COVID-19 vaccines and COVID-19 therapeutics news headlines appearing on a daily basis, the casual observer could be forgiven for assuming that biotech stocks had a great 2021. That was not the case, unfortunately. There has been a sector rotation in 2021 from growth to value stocks. We are hopeful and have fundamental reasons to believe that 2022 will be a more positive year for the biotech sector and that this growth sector will once again be favored by investors. With pharmaceutical companies flushed with cash on their balance sheets, we could also see a year of increased M&A activity in the sector.